Reported about 17 hours ago
AbbVie (ABBV) experienced a significant increase in share price after Leerink Partners upgraded the stock to Outperform, indicating that the recent sell-off presents a buying opportunity for investors. The pharmaceutical company's shares had previously dropped due to disappointing results from a mid-stage trial for its schizophrenia drug, which competes with Bristol-Myers Squibb (BMY).
Source: YAHOO